Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies

被引:38
作者
Horowitz, Mark Abie [1 ,2 ]
Taylor, David [3 ,4 ]
机构
[1] Univ Coll London UCL, Div Psychiat, London, England
[2] North East London NHS Fdn Trust NELFT, Res & Dev Dept, London, England
[3] Maudsley Hosp & Inst Psychiat, Pharm & Pathol, London, England
[4] Kings Coll London, Psychopharmacol, London, England
关键词
Withdrawal; discontinuation; SSRI; SNRI; confounding; DOUBLE-BLIND; SYMPTOMS; PREVENTION; PAROXETINE; DEPRESSION; DRUG; METAANALYSIS; ESCITALOPRAM; AGOMELATINE; EFFICACY;
D O I
10.1192/bja.2021.62
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
We now recognise that withdrawal symptoms from antidepressants are common, and can be severe and long-lasting in some people. Many withdrawal symptoms overlap with symptoms of anxiety or depression, making it difficult to distinguish withdrawal from relapse. We describe how their onset soon after dose reduction, the association of psychological with physical symptoms, their prompt response to reinstatement, and their typical 'wave' pattern of onset, peak and resolution can help distinguish withdrawal symptoms from relapse. We also examine evidence that suggests that antidepressant withdrawal symptoms are misdiagnosed as relapse in discontinuation studies aimed at demonstrating the ability of antidepressants to prevent future relapse (relapse prevention properties). In these discontinuation studies people have their antidepressants stopped abruptly, or rapidly, making withdrawal symptoms very likely, and little effort is made to measure withdrawal symptoms or distinguish them from relapse. We conclude that there is currently no robust evidence for the relapse prevention properties of antidepressants, and current guidance might need to be re-evaluated.
引用
收藏
页码:297 / 311
页数:15
相关论文
共 62 条
[1]   Effects of Treatment Discontinuation in Clinical Psychopharmacology [J].
Baldessarini, Ross J. ;
Tondo, Leonardo .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2019, 88 (02) :65-70
[2]   Discontinuation symptoms in depression and anxiety disorders [J].
Baldwin, David S. ;
Montgomery, Stuart A. ;
Nil, Rico ;
Lader, Malcolm .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (01) :73-84
[3]   A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder [J].
Baldwin, DS ;
Cooper, JA ;
Huusom, AKT ;
Hindmarch, I .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (03) :159-169
[4]   Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration [J].
Borges, Silvana ;
Chen, Yeh-Fong ;
Laughren, Thomas P. ;
Temple, Robert ;
Patel, Hiren D. ;
David, Paul A. ;
Mathis, Mitchell ;
Unger, Ellis ;
Yang, Peiling ;
Khin, Ni A. .
JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (03) :205-214
[5]  
Burn W., 2020, Stopping antidepressants. Stopping antidepressants
[6]   Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications [J].
Cosci, Fiammetta ;
Chouinard, Guy .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 89 (05) :283-306
[7]   Serotonin reuptake inhibitor withdrawal [J].
Coupland, NJ ;
Bell, CJ ;
Potokar, JP .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (05) :356-362
[8]  
Davies J., 2018, Antidepressant withdrawal: A survey of patients' experience by the all-party parliamentary group for prescribed drug dependence
[9]   A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? [J].
Davies, James ;
Read, John .
ADDICTIVE BEHAVIORS, 2019, 97 :111-121
[10]   Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review [J].
Fava, Giovanni A. ;
Benasi, Giada ;
Lucente, Marcella ;
Offidani, Emanuela ;
Cosci, Fiammetta ;
Guidi, Jenny .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2018, 87 (04) :195-203